NOVACYT, the French specialist in fully automated liquid based cytology for cancer screening, has secured $852K in new funding. Founded in 2006 by an experienced team from biotech and industrial companies, the V茅lizy-Villacoublay-based firm develops and markets advanced solutions designed to improve laboratory workflow and throughput.
Recognized as a highly innovative company by GENOPOLE and OSEO, NOVACYT positions itself as a market leader with proprietary equipment and devices. Its multipurpose platform streamlines GYN and NON GYN cytology, multi slide preparation, and pre-aliquoting for reflex testing by molecular biology, increasing laboratory efficiency.
